Effect of Febuxostat on Flow Mediated Diameter in hyperuricemia patients with chronic kidney disease 5D.

Effect of Febuxostat on Flow Mediated Diameter in hyperuricemia patients with chronic kidney disease 5D. - Effect of Febuxostat on Flow Mediated Diameter. (FFMD-5D study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014787

Enrollment

Registered

2014-08-11

Start date

2014-08-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricemia

Interventions

febuxostat administration life habit improvement

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients with maintenance hemodailaysis must match all conditions below. Patients older than 20 years old. Patients with serum uric acid level over 7.0mg/dl. Patients agreed with consent form.

Exclusion criteria

Exclusion criteria: Patients who take allopurinol, probenecid, bucolome, febuxostat. Patients with history of hypersensitivity to febuxostat. Patients who take mercaptopurine, azathiopurine, pyrazinamide or ethambutol. Patients participant to other clinical trials within recent 4 weeks. Patients judged not to be suitable as a subject by attending doctor.

Design outcomes

Primary

Measure	Time frame
Flow Mediated Diameter:FMD	—

Secondary

Measure	Time frame
the change of FMD. the change of serum uric acid level achievement rate of the target serum uric acid level(<6.0mg/dl) oxidative stress inflammatory maker gouty attack adverse event	—

Countries

Japan

Contacts

Public ContactYuki Tsuruta

Tsuruta clinic Dialysis center

yuki@kb4.so-net.ne.jp03-5375-7600

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026